Barclays has initiated coverage on McKesson Corp (MCK) with an Overweight rating, marking the firm's first assessment of the company. This rating reflects Barclays' analysis of McKesson's business fundamentals and growth prospects within the healthcare industry.
Headquartered in Irving, Texas, McKesson engages in providing healthcare services, employing 43,000 full-time staff. The company's U.S. Pharmaceutical segment distributes a variety of pharmaceutical products, including branded, generic, and specialty drugs, while its Prescription Technology Solutions segment addresses challenges related to medication access and affordability. Additionally, McKesson's Medical-Surgical Solutions segment offers supply distribution and logistics to healthcare providers.
Currently, McKesson boasts a market capitalization of $98.8 billion, a trailing P/E ratio of 24.51, and an EPS of 32.12. The company also offers a notable dividend yield of 41.1%. Looking ahead, McKesson is set to report its next earnings on August 4, 2026, with an estimated EPS of $9.87 and projected revenue of $106.9 billion.
Analyst ratings, such as this one from Barclays, serve as professional opinions grounded in research and financial modeling. While they can provide valuable insights, these ratings reflect assumptions that may evolve as new information becomes available. Investors should consider a range of factors, including company fundamentals and industry trends, when making investment decisions.
As of December 1, 2025, the analyst consensus on McKesson is categorized as a Buy, with 7 Strong Buy ratings, 11 Buy ratings, and 3 Hold ratings among a total of 21 analysts.